Poster Presentations
The poster session will be held on Thursday, June 1, 2023 from 18h00 to 19h30 as part of the Welcome Reception in Saal 1 (Hall 1).
Poster presenters should be available at the poster boards during this time for questions and discussion. All posters will be displayed in Saal 1 (Hall 1) during the entire congress.
Poster size
The poster format is A0 portrait format (1189 x 841 mm). Fixing material will be provided on-site at the registration desk.
Abstract ID
Poster number
Title
Presenting author
75
P-01
The role of cetrimide body wash and prophylactic antibiotics in reducing Catheter related blood stream infections in Therapeutic Plasma exchange patients: A Game changer
S. Viswanathan
Kuala Lumpur Hospital, Neurology,
Kuala Lumpur, MY
16
P-02
Long-term therapeutic plasmpheresis and successful treatment of dysphagia in a patient suffering from myasthenia gravis and chronic kidney disease.
V. Athanasiadou
National and Kapodistrial University of Athens, Nephrology Clinic / Aretaieio Hospital, Athens, GR
24
P-03
Evinacumab reduces EU and US apheresis eligibility in patients with homozygous familial hypercholesterolemia
P. Moriarty
The University of Kansas Medical Center, Department of Clinical Pharmacology, Kansas City, Kansas, US
2
P-04
Cytokine modulation in abdominal septic shock via the crucial role of IL-6 signaling in endothelial dysfunction
T. Ueno
Tokyo Medical University, Kidney Transplant Center, Renal Division, Hachioji, Tokyo, JP
21
P-05
Therapeutic plasma exchange in Paraneoplastic encephalitis – Case report
J. Ferreira
Centro Hospitalar e Universitário de Coimbra, Serviço de Sangue e Medicina Transfusional, Coimbra, PT
58
P-06
The effect of continuous plasma filtration with dialysis (PDF) in patients with sepsis and acute liver failure with/without surgical intervention
Y. Eguchi
Shiga University of Medical Science, Critical and Intensive Care Medicine, Otsu, JP
60
P-07
Selective cfDNA/NETs apheresis with NucleoCapture® in a Porcine Intensive Care Sepsis Model: A blinded randomised controlled trial
A. Aswani
Santersus AG, Zurich, Switzerland
Guy’s and St Thomas’ NHS Foundation Trust, Critical Care Medicine, London, UK
68
P-08
Selective cfDNA/NETs apheresis with NucleoCapture® in a Prolonged Clinically Relevant Porcine Intensive Care Sepsis Model
A. Aswani
Santersus AG, Zurich, Switzerland
Guy’s and St Thomas’ NHS Foundation Trust, Critical Care Medicine, London, UK
20
P-09
Three cases of long COVID syndrome treated with immunoadsorption – possible profit in the improvement of quality of life
A. Al-Nakkash
DHZ gGmbH, Köln, DE
84
P-10
Immunoadsorption in anti-MDA5-positive refratory amyopathic dermatomyositis
A. Sayer-Klink
Jena University Hospital -Friedrich Schiller University Jena, Institute of Transfusion Medicine, Jena, DE
1
P-11
Bifidobacterium longum R0175 Protects Mice against APAP-induced Liver Injury by Modulating the Nrf2 Pathway
S. Li
Zhejiang University, School of Medicine, Hangzhou, CN
7
P-12
Akkermansia muciniphila-derived acetate activates hepatic AMPK-SIRT1-PGC1α to alleviate lipid peroxidation in metabolic-associated fatty liver disease
A. Zhuge
Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, Hangzhou, CN
43
P-13
Therapeutic plasma exchange rescues SLE-associated bilateral optic neuritis: A case report.
W. Pongsittisak
Navamindradhiraj University, Nephrology and Renal Replacement Therapy Division, Department of Internal Medicine, Facult of Medicine Vajira Hospital, Bangkok, TH
56
P-14
The development of functional biliary tree organoids with network structures and serotonin expression in decellularized liver scaffolds
J. Li
The First Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Hangzhou, CN
57
P-15
Bempedoic acid and cardiovascular outcomes in statin-intolerant patients
P. Moriarty
University of Kansas Medical Center, Kansas City, Kansas, US
64
P-16
Lipoprotein-Apheresis therapy, for patients with an elevated Lipoprotein(a) and progressive cardiovascular diseases, reduces the development of calcific aortic valve stenosis.
P. Moriarty
University of Kansas Medical Center, Kansas City, Kansas, US
49
P-17
Problems of achieving the lipid spectrum target levels in patients with familial hypercholesterolemia
U. Julius
University Hospital Dresden, Dresden, DE